A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, dry eye, retinal diseases and other diseases of the eye
News Highlights
Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval ... Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (ne... Aerie Pharmaceuticals Submits Marketing Authorisation Application for Rocla...STOCK Quote
NASDAQ: AERI
$22.56USD
Jan 21, 4:00 PM ET
VOLUME
1,092,298
DAY LOW/HIGH
$22.30/$22.97
52 - WEEK LOW/HIGH
$17.15/$50.10
